Market Newsdesk

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share. The offerings closed on February 2, 2026.

In addition to the shares sold in the underwritten public offering, Lexicon granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public offering prices, less underwriting discounts and commissions, which remains outstanding. An affiliate of Invus, L.P. (the “Private Placement Purchaser”) has the option to purchase up to an additional 94,855 shares of Series B Convertible Preferred Stock, which are convertible into 4,742,744 shares of common stock, at a price of $65.00 per share of Series B Convertible Preferred Stock, to the extent the underwriters exercise their option to purchase additional shares of common stock.

The optional securities being offered to the Private Placement Purchaser will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). Both the option held by the underwriters to purchase additional shares of common stock and the option held by the Private Placement Purchaser to purchase additional shares of Series B Convertible Preferred Stock will expire 30 days after the closing of the issuances.

Lexicon intends to use the net proceeds from the offering and the concurrent private placement, including any proceeds from the exercise of either option to purchase additional shares, (i) to fund the continued research and development of its drug candidates and (ii) for working capital and other general corporate purposes.

Jefferies and Piper Sandler are acting as joint book-running managers for the public offering. H.C. Wainwright & Co. is acting as lead manager for the public offering.

A shelf registration statement on Form S-3 relating to the public offering was filed with the U.S. Securities and Exchange Commission (“SEC”) on August 2, 2024 and declared effective by the SEC on August 15, 2024 (File No. 333-281208). The shares of common stock issued in the concurrent private placement have not been registered under the Securities Act, or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States except pursuant to registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act and, in each case, in compliance with other applicable securities laws. A preliminary prospectus supplement, accompanying prospectus relating to the public offering and final prospectus supplement have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 821-7388; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at [email protected].

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the offering, the use of proceeds from the offering and the grant of the option to the underwriters and the private placement purchaser to purchase additional shares, are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s Annual Report on Form 10-K for the year ended December 31, 2024, and our subsequently filed Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, the quarter ended June 30, 2025 and the quarter ended September 30, 2025 and other subsequent disclosure documents filed with the SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]

Registration Statement

Lexicon has filed a registration statement (including a prospectus) with the SEC for the equity offering to which this communication relates. Before you invest, you should read the final prospectus supplement and the accompanying prospectus in that registration statement and other documents Lexicon has filed with the SEC for more complete information about Lexicon and the equity offering. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 821-7388; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at [email protected].

FORT WORTH, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — On February 3, 2026, Tandy Leather Factory, Inc. (the “Company”, Nasdaq: TLF) announced that its Board of Directors had declared the payment of a special cash dividend to its stockholders of $0.75 per share of common stock held. The dividend will be paid on or about February 24, 2026.

Because the dividend amount is more than 25% of the current market price of the Company’s common stock, the ex-dividend date will be February 25, 20265, in accordance with Nasdaq UPC Rule 11140. On that date, the Company’s common stock will begin trading without the right to receive the special dividend, and the price will be adjusted accordingly.

Tandy Leather Factory, Inc. (http://www.tandyleather.com), headquartered in Fort Worth, Texas, is a specialty retailer of a broad product line, including leather, leatherworking tools, buckles and adornments for belts, leather dyes and finishes, saddle and tack hardware, and do-it-yourself kits. The Company distributes its products through its 101 North American stores located in 40 US states and six Canadian provinces, and one store located in Spain. Its common stock trades on the Nasdaq Capital Market under the symbol “TLF”. To be included on Tandy Leather Factory’s email distribution list, go to: http://www.b2i.us/irpass.asp?BzID=1625&to=ea&s=0.

Contact: Jeff Gramm, Tandy Leather Factory, Inc.  (817) 872-3200 or [email protected]

This news release may contain statements regarding future events, occurrences, circumstances, activities, performance, outcomes and results that are considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Actual results and events may differ from those projected as a result of certain risks and uncertainties. These risks and uncertainties include but are not limited to: changes in general economic conditions, negative trends in general consumer-spending levels, failure to realize the anticipated benefits of opening retail stores; availability of hides and leathers and resultant price fluctuatio
ns; change in customer preferences for our product, and other factors disclosed in our filings with the Securities and Exchange Commission.  These forward-looking statements are made only as of the date hereof, and except as required by law, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

TROY, Mich., Feb. 06, 2026 (GLOBE NEWSWIRE) — Presurance Holdings, Inc. (Nasdaq: PRHI) (“Presurance” or the “Company”) today announced the commencement of its rights offering, previously detailed in the Company’s Current Report on Form 8-K filed on January 28, 2026.

Shareholders of record on February 6, 2026 are now being distributed a dividend of one non-transferable Subscription Right (“Subscription Right”) for each share of common stock owned on the record date.

Each Subscription Right, when exercised before the expiration date of 5:00 p.m. New York City time on February 24, 2026, entitles the holders to purchase 1.145 shares of Presurance common stock at a subscription price of $1.00 per share.

A shareholder may exercise such shareholder’s subscription rights by properly completing and executing the rights certificate together with any required signature guarantees and forwarding it, together with full subscription payment, to the Subscription Agent prior to the expiration of the rights offering.

A shareholder who is a beneficial owner of shares of Presurance common stock that are registered in the name of a broker, custodian bank or other nominee, or a shareholder who holds Presurance common stock certificates and would prefer to have an institution conduct the transaction relating to the subscription rights on the shareholder’s behalf, should instruct such shareholder’s broker, custodian bank or other nominee or institution to exercise the subscription rights and deliver all documents and payment on your behalf prior to 5:00 p.m., New York City time, on February 24, 2026, which is the expiration of the rights offering.

Brokers may require earlier action to process orders. Exercise instructions received after the expiration date and time will not be honored, so investors who wish to participate must exercise ahead of the deadline.

Any payment received from the exercise of the subscription right and not applied to such exercise of the subscription rights will be refunded to the shareholder without interest or penalty.  

For any questions or further information about this rights offering, please contact Broadridge Corporate Issuer Solutions, LLC at (855) 739-5068 or by email ([email protected]).

The Rights Offering is being made pursuant to Presurance’s effective registration statement on Form S-1 (File No. 333-292735), and a prospectus containing the detailed terms of the rights offering filed with the SEC. The information in this press release is not complete and is subject to change. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction. The rights offering is being made only by means of a prospectus. The prospectus incorporates all the Company’s SEC filings by reference. Copies of the prospectus, are being distributed to all subscription right recipients and may also be obtained free of charge at the website maintained by the SEC at


www.sec.gov


 or by contacting the information agent for the offering.

About Presurance Holdings

Presurance Holdings, Inc. is a Michigan-based property and casualty holding company. Through its subsidiaries, the Company provides specialty insurance coverage designed to protect individuals, businesses, and communities, with a focus on disciplined growth and long-term value creation. The Company trades on the Nasdaq Capital Market under the symbol PRHI. Additional information can be found on the Company’s website at ir.PREHLD.com.

UNIONDALE, N.Y., Feb. 06, 2026 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced that it is scheduled to release fourth quarter 2025 financial results before the market opens on Friday, February 27, 2026. The Company will host a conference call to review the results at 10:00 a.m. Eastern Time on February 27, 2026.

A live webcast and replay of the conference call will be available at www.arbor.com in the investor relations section of the Company’s website. Those without web access should access the call telephonically at least ten minutes prior to the conference call. The dial-in numbers are (800) 267-6316 for domestic callers and (203) 518-9783 for international callers. Please use participant passcode ABRQ425 when prompted by the operator.

A telephonic replay of the call will be available until March 6, 2026. The replay dial-in numbers are (800) 839-1192 for domestic callers and (402) 220-0402 for international callers.

About Arbor Realty Trust, Inc.

Arbor Realty Trust, Inc. (NYSE: ABR) is a nationwide real estate investment trust and direct lender, providing loan origination and servicing for multifamily, single-family rental (SFR) portfolios, and other diverse commercial real estate assets. Headquartered in New York, Arbor manages a multibillion-dollar servicing portfolio, specializing in government-sponsored enterprise products. Arbor is a leading Fannie Mae DUS® lender, Freddie Mac Optigo® Seller/Servicer, and an approved FHA Multifamily Accelerated Processing (MAP) lender. Arbor’s product platform also includes bridge, CMBS, mezzanine, and preferred equity loans. Rated by Standard and Poor’s and Fitch Ratings, Arbor is committed to building on its reputation for service, quality, and customized solutions with an unparalleled dedication to providing our clients excellence over the entire life of a loan.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the “Grant Date”), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36^th) of the remaining shares vesting each one-month period thereafter. One-third (1/3^rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor that selectively targets EGFR exon 20 and atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 70,000 options to purchase shares of the company’s common stock at an exercise price of $10.72 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, February 2, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
[email protected]
617-283-2856

Hong Kong, Feb. 06, 2026 (GLOBE NEWSWIRE) — SOLOWIN HOLDINGS (Nasdaq: AXG) (“AXG” or the “Company”), a leading financial technology firm bridging traditional and digital assets, today announced a partnership with Taobao Shangou,a subsidiary of Alibaba Group and Hangzhou Bossen, to implement an innovative model integrating “high-quality carbon assets + consumer platform incentives + on-chain carbon credit circulation.” This initiative establishes a replicable pathway for scaling carbon assets applications and advancing inclusive carbon reduction.

Achieving carbon peak and carbon neutrality is a major national strategic objective in China. On August 25, 2025, the General Offices of the Communist Party of China Central Committee and the State Council issued a guideline to advance China’s green and low-carbon transition and strengthen the construction of the national carbon trading market. The document emphasized improving the inclusive carbon reduction mechanism and accelerating the scaled application of carbon assets. In response, on March 25, 2025, the Zhejiang Provincial Development and Reform Commission, the province’s top economic planning authority, released the Key Work Points for Carbon Peaking and Carbon Neutrality in Zhejiang Province by 2025, outlining priorities including advancing green, low-carbon transitions in key sectors and promoting carbon asset initiatives.

Against this national and regional policy backdrop, and supported by favorable industry trends, AXG launched this collaboration to apply its blockchain expertise to the commercialization of inclusive carbon reduction in China. Ferion, AXG’s one-stop asset tokenization platform, provides a comprehensive technical solution and implementation framework for the compliant on-chain management of carbon assets. Leveraging its established capabilities in asset tokenization and blockchain infrastructure, Ferion facilitates condition verification, rights confirmation and mapping, circulation recording, and full lifecycle management of the carbon assets, ensuring a secure and transparent technical foundation for their integration into consumer scenarios.

Within the partnership framework, Hangzhou Bossen supplies high-quality carbon assets to Alibaba Group’s food delivery platform, Taobao Shangou, where carbon benefits are embedded into the platform’s incentive system. Through AXG’s Ferion system, these benefits are then allocated to Taobao Shangou users as rewards based on their carbon reduction behaviors, such as opting for green delivery or making low-carbon product choices, thereby encouraging consumers to participate in emission reduction through everyday consumption.

Dr. Thomas Zhu, Co-Founder and Chief Executive Officer of AlloyX Group, a subsidiary of AXG, commented: “Our collaboration with Taobao Shangou and Hangzhou Bossen, connects consumers, platforms and financial services, establishing a benchmark closed-loop model from carbon assets to consumer incentives and ultimately to carbon asset buyback. We believe this innovative business model will create a win-win scenario in terms of both social and platform value, and serve as a demonstrative case for the integration of green finance and digital technology, with the potential to further drive the broader adoption of inclusive carbon reduction.”

About TAOBAO SHANGOU

Founded in 2008, Taobao Shangou (formerly Ele.me) is a leading local lifestyle platform in China under Alibaba Group. The platform is committed to providing “worry-free and on-time delivery” home services and advancing the digitalization of the local lifestyle market through technological innovation. To date, Taobao Shangou’s food delivery services cover more than 2,000 cities across China.

About HANGZHOU BOSSEN

Hangzhou Bossen Enterprise Management Co., Ltd, focuses on carbon asset development and management and green financial technology innovation. The company is dedicated to addressing environmental challenges through market-based economic mechanisms, providing comprehensive, one-stop green economic solutions for various industries.

About SOLOWIN HOLDINGS

SOLOWIN HOLDINGS (Nasdaq: AXG) is a global leading financial technology firm focused on digital currency payments and asset tokenization. Founded in 2016, it has dedicated to bridging traditional and decentralized finance by building a secure, efficient and compliant financial infrastructure that provides integrated digital asset solutions for global investors and institutions. Leveraging its Hong Kong Securities and Futures Commission (SFC)-licensed subsidiary Solomon JFZ (Asia) Holdings Limited, along with other key subsidiaries such as AlloyX Group and AX Coin, the Company has developed a multi-jurisdictional, vertically integrated, enterprise-grade new financial platform encompassing global stablecoin payments, corporate treasury and private wealth management and tokenization as a service. Backed by leading international institutional investors, the Company manages compliant and transparent digital assets that are closely connected to the real economy. The Company is committed to establishing itself as a leading global digital asset financial platform, driving the seamless convergence of traditional finance and the digital assets ecosystem.

For more information, visit the Company’s website at https://www.alloyx.com or investor relations webpage at https://ir.alloyx.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company has attempted to identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries please contact:

SOLOWIN HOLDINGS

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]